公司概述
Equillium, Inc. operates as a clinical-stage biotechnology company dedicated to developing therapeutics for severe autoimmune and inflammatory, or immuno-inflammatory disorders that present unmet medical needs in the United States. This sector classification places the company within the broader Healthcare industry, specifically focusing on biotechnology research and the potential commercialization of novel drug candidates. The company's current market capitalization stands at $120.76M, while its annual revenue is listed as N/A, and the number of employees is also recorded as N/A. These valuation figures indicate that Equillium, Inc. is a small-cap entity with limited historical revenue data, characteristic of a clinical-stage firm where value is derived primarily from the potential of its lead product candidate, Itolizumab (EQ001), rather than established commercial sales. The absence of reported revenue and employee count suggests the company is in a pre-revenue or early development phase where capital allocation is heavily weighted toward research and development activities to advance its immuno-modifying monobody technology through clinical trials.
财务健康
The company reports a Net Income (TTM) of $-22,398,000 and an EBITDA of $-23,518,000, while Revenue (TTM) is not available. The significant gap between reported revenue figures (which are unavailable) and the substantial net loss reveals a cost structure dominated by research and development expenditures typical for clinical-stage biotechnology firms that have not yet achieved commercial product launch. Free Cash Flow stands at $-14,327,250, indicating that the company is currently consuming cash reserves to fund its operations and clinical trials rather than generating liquidity from commercial activities. This negative free cash flow position limits immediate financial flexibility but is a standard characteristic of companies in the development phase that must burn cash to progress their assets. Analysis of the margins shows a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, reflecting that the company has not yet generated positive profitability from its operations. The balance sheet shows a Cash position of $30.28M against Total Debt of $719,000, with a Debt to Equity ratio of 2.51, suggesting a capital structure that relies heavily on equity financing or has a high equity base relative to its minimal debt obligations. The Current Ratio is 10.58, which indicates a very strong short-term liquidity position with current assets significantly exceeding current liabilities. Return on Equity is -94.0% and Return on Assets is -51.4%, metrics that reveal management is currently destroying value in traditional terms due to heavy investment losses, yet these negative returns are expected for a company with no commercial product sales.
估值评估
The company has a Forward P/E of -7.28 and a Trailing P/E (TTM) listed as N/A, implying that the market is pricing the stock based on forward expectations rather than historical earnings, which is standard for unprofitable biotechnology firms. The Price to Book ratio is 4.11, indicating that the market values the company at a significant premium over its tangible book value, reflecting the high potential value assigned to its intellectual property and clinical pipeline assets. The Price to Sales ratio is N/A and the EV/EBITDA is -3.88, suggesting that traditional sales-based or earnings-based valuation metrics are not applicable due to the lack of revenue and negative earnings. The stock has reached a 52-Week High of $2.70 and a 52-Week Low of $0.27, meaning the current trading price sits somewhere within this wide range, reflecting the high volatility inherent in pre-revenue biotech stocks. The Beta is 1.74, which explains that the stock's price volatility is significantly higher than that of the broader market, moving approximately 74% more than the market index in response to general market fluctuations.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, indicating that the company has no historical growth trajectory to analyze as it has not yet generated commercial revenue. Since the company is not a dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, all available capital must be reinvested into research, development, and clinical trial expansion rather than distributed to shareholders. The absence of a dividend policy is consistent with the business model of a clinical-stage biotechnology company that prioritizes capital retention to fund the costly process of bringing therapeutics to market. Overall, the growth and income profile is defined entirely by the potential future commercialization of its drug candidates rather than current revenue expansion or income generation for investors.